Published in Vaccine Weekly, June 8th, 1998
The grant was given pursuant to the Small Business Innovation Research Program (SBIR) of the U.S. National Institute of Allergy and Infectious Diseases (NIAID).
Daniel Zimmerman, Cel-Sci Corp., said, "We have shown protection against herpes simplex infectivity in animals. Our ultimate goal is to bring to market a preventive and therapeutic vaccine against herpes simplex infection in humans for which there is no approved vaccine or curative treatment available."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.